Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Potential delays in adoption for new products like Visium HD and GEM-X. Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over ...

Leerink Partners cut shares of 10x Genomics (NASDAQ:TXG – Free Report) from an outperform rating to a market perform rating ...

and the pricing challenges from the GEM-X transition are expected to ease by the fourth quarter. William Blair keeps the ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

10x Genomics (NASDAQ:TXG), a leading player in the single-cell ... Curious if TXG is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the ...

10x Genomics disclaims any intention or obligation ... We introduced a new microfluidic architecture, GEM-X and a slate of new products and capabilities. Once again, we raised the bar on ...